

# Carolyn D Runowicz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5385235/publications.pdf>

Version: 2024-02-01

100  
papers

11,380  
citations

87888

38  
h-index

38395

95  
g-index

103  
all docs

103  
docs citations

103  
times ranked

12433  
citing authors

#	ARTICLE	IF	CITATIONS
1	Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 2037-2048.	1.6	51
2	Association Between Race/Ethnicity and Survival in Women With Advanced Ovarian Cancer. Cureus, 2021, 13, e16070.	0.5	1
3	Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology, 2019, 37, 3152-3165.	1.6	117
4	Ovarian cancer statistics, 2018. Ca-A Cancer Journal for Clinicians, 2018, 68, 284-296.	329.8	2,224
5	The MD CaREs initiative: Tailoring oncology education to ethnically and culturally diverse students.. Journal of Clinical Oncology, 2018, 36, 11019-11019.	1.6	0
6	American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. Ca-A Cancer Journal for Clinicians, 2016, 66, 43-73.	329.8	497
7	American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. Journal of Clinical Oncology, 2016, 34, 611-635.	1.6	651
8	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clinic Proceedings, 2015, 90, 996-1000.	3.0	128
9	Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2012, 30, 1553-1561.	1.6	430
10	Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial. Menopause, 2011, 18, 17-22.	2.0	56
11	Multimodal therapy in the treatment of vaginal adenocarcinoma arising from endocervicosis. Gynecologic Oncology, 2011, 120, 158-159.	1.4	2
12	Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). American Journal of Obstetrics and Gynecology, 2011, 205, 535.e1-535.e5.	1.3	48
13	Prevalence and Prognostic Role of Triple-Negative Breast Cancer by Race: A Surveillance Study. Clinical Breast Cancer, 2011, 11, 332-341.	2.4	21
14	Chemotherapy in Pregnancy. Clinical Obstetrics and Gynecology, 2011, 54, 602-618.	1.1	61
15	Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer. International Journal of Gynecological Cancer, 2010, 20, 772-780.	2.5	52
16	Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: A New York Cancer Consortium Study. Gynecologic Oncology, 2010, 116, 442-446.	1.4	14
17	Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment. Gynecologic Oncology, 2010, 119, 451-456.	1.4	55
18	Challenges to National Cancer Instituteâ€œSupported Cooperative Group Clinical Trial Participation: An ASCO Survey of Cooperative Group Sites. Journal of Oncology Practice, 2010, 6, 114-117.	2.5	19

#	ARTICLE	IF	CITATIONS
19	Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer. Cancer Prevention Research, 2010, 3, 696-706.	1.5	560
20	The Impact of the Privacy Rule on Cancer Research: Variations in Attitudes and Application of Regulatory Standards. Journal of Clinical Oncology, 2009, 27, 4014-4020.	1.6	9
21	Ovarian Cancer Screening and Early Detection. Women's Health, 2009, 5, 693-699.	1.5	16
22	Human papillomavirus testing for primary cervical cancer screening. Current Oncology Reports, 2008, 10, 533-537.	4.0	5
23	Intraperitoneal Chemotherapy in Ovarian Cancer: An Update. Cancer Journal (Sudbury, Mass ), 2008, 14, 7-9.	2.0	4
24	Molecular Screening for Cervical Cancer – Time to Give up Pap Tests?. New England Journal of Medicine, 2007, 357, 1650-1653.	27.0	52
25	Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia. International Journal of Cancer, 2007, 120, 55-59.	5.1	13
26	A Midpoint Assessment of the American Cancer Society Challenge Goal to Decrease Cancer Incidence by 25% Between 1992 and 2015. Ca-A Cancer Journal for Clinicians, 2007, 57, 326-340.	329.8	28
27	Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecologic Oncology, 2007, 106, 453-460.	1.4	127
28	GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Modern Pathology, 2006, 19, 1429-1436.	5.5	60
29	Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: A brief communication from the New York Phase II consortium. Gynecologic Oncology, 2006, 100, 160-165.	1.4	29
30	Investment in Cancer Control and Research: A Sure Bet. Ca-A Cancer Journal for Clinicians, 2006, 56, 9-10.	329.8	1
31	A midpoint assessment of the American Cancer Society challenge goal to halve the U.S. cancer mortality rates between the years 1990 and 2015. Cancer, 2006, 107, 396-405.	4.1	42
32	Clarifying Cancer Mortality Rates. Science, 2006, 313, 171c-172c.	12.6	1
33	Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes<SUBTITLE>The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2006, 295, 2727.	7.4	1,499
34	Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. American Journal of Obstetrics and Gynecology, 2005, 192, 1230-1237.	1.3	97
35	Preserving Fertility After Cancer. Ca-A Cancer Journal for Clinicians, 2005, 55, 211-228.	329.8	87
36	Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute, 2005, 97, 1652-1662.	6.3	1,192

#	ARTICLE	IF	CITATIONS
37	Combination of Imatinib Mesylate with Autologous Leukocyte-Derived Heat Shock Protein and Chronic Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2005, 11, 4460-4468.	7.0	100
38	Cervical Cancer Screening. <i>Surgical Oncology Clinics of North America</i> , 2005, 14, 777-797.	1.5	11
39	Biweekly 72-Hour 9-Aminocamptothecin Infusion As Second-Line Therapy for Ovarian Carcinoma: Phase II Study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 120-126.	1.6	17
40	Evaluation of low-dose intraperitoneal interferon- $\beta$ for palliation of ascites in patients with non-ovarian gynecologic malignancies. <i>Gynecologic Oncology</i> , 2003, 89, 420-423.	1.4	4
41	Extended-field radiotherapy and high-dose-rate brachytherapy in carcinoma of the uterine cervix. <i>Cancer</i> , 2003, 97, 1781-1788.	4.1	41
42	Current Therapies in Ovarian Cancer. <i>Cancer Investigation</i> , 2003, 21, 148-156.	1.3	23
43	American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer. <i>Journal of Lower Genital Tract Disease</i> , 2003, 7, 67-86.	1.9	41
44	Early Diagnosis and Screening for Ovarian Cancer. , 2003, , 219-229.		0
45	Association of Tamoxifen and Uterine Sarcoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 2758-2760.	1.6	201
46	Can Radiological Procedures Replace Histologic Examination in the Evaluation of Abnormal Vaginal Bleeding?. <i>Obstetrics and Gynecology</i> , 2002, 99, 529-530.	2.4	4
47	Expression of COX-2, Ki-67, Cyclin D1, and P21 in Endometrial Endometrioid Carcinomas. <i>International Journal of Gynecological Pathology</i> , 2002, 21, 147-154.	1.4	67
48	Can radiological procedures replace histologic examination in the evaluation of abnormal vaginal bleeding?. <i>Obstetrics and Gynecology</i> , 2002, 99, 529-530.	2.4	4
49	American Cancer Society Guidelines for the Early Detection of Cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2002, 52, 8-22.	329.8	615
50	American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2002, 52, 342-362.	329.8	782
51	Phase I clinical trial of parenteral hydroxyurea in combination with pelvic and para-aortic external radiation and brachytherapy for patients with advanced squamous cell cancer of the uterine cervix. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 637-642.	0.8	9
52	Two fractions of high-dose-rate brachytherapy in the management of cervix cancer: clinical experience with and without chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 702-706.	0.8	38
53	Surgery â€œAin'tâ€ Going to Cut It. Are We Ready?. <i>Gynecologic Oncology</i> , 2002, 84, 357-359.	1.4	2
54	THE WISDOM OF HORMONE-REPLACEMENT THERAPY IN SURVIVORS OF OVARIAN AND ENDOMETRIAL CANCER. <i>Surgical Clinics of North America</i> , 2001, 81, 987-993.	1.5	2

#	ARTICLE	IF	CITATIONS
55	Pattern of Lymph Node Metastases in Clinically Unilateral Stage I Invasive Epithelial Ovarian Carcinomas. <i>Gynecologic Oncology</i> , 2001, 80, 56-61.	1.4	119
56	Allelotype of Papillary Serous Peritoneal Carcinomas. <i>Gynecologic Oncology</i> , 2001, 82, 69-76.	1.4	20
57	Gynecologic Surveillance of Women on Tamoxifen: First Do No Harm. <i>Journal of Clinical Oncology</i> , 2000, 18, 3457-3458.	1.6	24
58	Screening for Gynecologic Malignancies. <i>Surgical Oncology Clinics of North America</i> , 1999, 8, 703-723.	1.5	13
59	Compliance with Papanicolaou Smear Screening Following Tubal Ligation in Women with Cervical Cancer. <i>Journal of Women's Health</i> , 1999, 8, 103-107.	0.9	5
60	Profound Thrombocytopenia in Previously Treated Patients with Recurrent Ovarian Carcinoma Receiving Topotecan. <i>Gynecologic Oncology</i> , 1998, 69, 175-176.	1.4	7
61	Can Precolposcopy Education Increase Knowledge and Decrease Anxiety?. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 1998, 27, 636-645.	0.5	28
62	The rectus abdominis myocutaneous flap. , 1998, 83, 510-520.		78
63	Conservative management of uterine rhabdomyosarcoma. <i>Obstetrics and Gynecology</i> , 1998, 92, 669-670.	2.4	3
64	Continuous Low-Dose Combined Hormone Replacement Therapy and the Risk of Endometrial Cancer. <i>Gynecologic Oncology</i> , 1997, 64, 425-430.	1.4	29
65	Pelvic exenteration for cervix cancer: Would additional intraoperative interstitial brachytherapy improve survival?. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 38, 143-148.	0.8	16
66	All-trans retinoic acid and interferon- $\gamma$ -2a in patients with metastatic or recurrent carcinoma of the uterine cervix. , 1997, 79, 1574-1580.		19
67	Mature Results of a Phase II Trial of Concomitant Cisplatin/Pelvic Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Cervix. <i>Gynecologic Oncology</i> , 1996, 61, 416-422.	1.4	45
68	Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1996, 174, 1151-1160.	1.3	10
69	Altered expression of transforming growth factor- $\beta$ 1 in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix. , 1996, 77, 1107-1114.		42
70	Promising new therapies in the treatment of advanced ovarian cancer. <i>Cancer</i> , 1995, 76, 2028-2033.	4.1	28
71	Office laparoscopy as a screening tool for early detection of ovarian cancer. <i>Journal of Cellular Biochemistry</i> , 1995, 59, 238-242.	2.6	6
72	Gynaecologic effects of tamoxifen. <i>Medical Oncology</i> , 1995, 12, 87-94.	2.5	6

#	ARTICLE	IF	CITATIONS
73	Lack of Efficacy of Interferon- $\beta$ Therapy in Recurrent, Advanced Cervical Cancer. Journal of Interferon and Cytokine Research, 1995, 15, 1011-1016.	1.2	14
74	A Prospective Randomized Comparison of an Attached Silver-Impregnated Cuff to Prevent Central Venous Catheter-Associated Infection. Gynecologic Oncology, 1995, 58, 92-100.	1.4	28
75	Early detection of abdominal pregnancy by maternal serum AFP+ screening. Prenatal Diagnosis, 1994, 14, 1155-1157.	2.3	12
76	DNA adducts in human and patas monkey material and fetal tissues induced by platinum drug chemotherapy. Reproductive Toxicology, 1994, 8, 207-216.	2.9	18
77	Lipid-Soluble Antioxidants: $\beta$ -Carotene and $\alpha$ -Tocopherol Levels in Breast and Gynecologic Cancers. Gynecologic Oncology, 1994, 55, 72-77.	1.4	23
78	Cecal Cancer in a Teenager Presenting with a Pelvic Mass: A Case Report and Review of the Literature. Gynecologic Oncology, 1994, 55, 149-151.	1.4	2
79	Platinum Chemotherapy during Pregnancy for Serous Cystadenocarcinoma of the Ovary. Gynecologic Oncology, 1993, 49, 92-94.	1.4	91
80	To P32 or Not to P32, That Is the Question. Gynecologic Oncology, 1993, 50, 139-140.	1.4	3
81	Taxol in ovarian cancer. Cancer, 1993, 71, 1591-1596.	4.1	59
82	Ovarian carcinoma of low malignant potential, infertility, and induction of ovulation—Is there a link?. American Journal of Obstetrics and Gynecology, 1992, 166, 853-854.	1.3	60
83	Lymph node sampling in patients with epithelial ovarian carcinoma. Gynecologic Oncology, 1992, 47, 143-145.	1.4	17
84	Advances in the screening and treatment of ovarian cancer. Ca-A Cancer Journal for Clinicians, 1992, 42, 327-349.	329.8	10
85	Adjuvant therapy for neuroendocrine small cell carcinoma of the cervix: Review of the literature. Gynecologic Oncology, 1991, 43, 167-172.	1.4	41
86	Heterogeneity in hormone receptor status in primary and metastatic endometrial cancer. Gynecologic Oncology, 1990, 38, 437-441.	1.4	34
87	A successful term pregnancy following the systemic and intraperitoneal administration of cisplatin chemotherapy. Gynecologic Oncology, 1990, 39, 378-380.	1.4	42
88	CA-125: A potential prognostic indicator in patients with cervical cancer?. Gynecologic Oncology, 1990, 40, 222-224.	1.4	7
89	Ovarian conservation in placental site trophoblastic tumor. Gynecologic Oncology, 1990, 37, 239-243.	1.4	20
90	CA 125 levels in patients with ovarian carcinoma undergoing autologous bone marrow transplantation. American Journal of Obstetrics and Gynecology, 1989, 160, 354-355.	1.3	2

#	ARTICLE	IF	CITATIONS
91	Colposcopic and cytologic detection of chronic lymphocytic leukemia. Gynecologic Oncology, 1989, 34, 106-108.	1.4	11
92	Arterial embolization in the management of abdominal and retroperitoneal hemorrhage. Gynecologic Oncology, 1989, 34, 131-135.	1.4	8
93	Concomitant cisplatin and radiotherapy in locally advanced cervical carcinoma. Gynecologic Oncology, 1989, 34, 395-401.	1.4	65
94	Immune Complexes in ovarian carcinoma. Gynecologic Oncology, 1989, 32, 350-353.	1.4	2
95	Adenocarcinoma arising in vulvar breast tissue. Cancer, 1988, 62, 2234-2238.	4.1	41
96	Detection of Human Papillomavirus Type 16 DNA in Peritoneal Washings from Patients with Cervical Carcinoma. Journal of Infectious Diseases, 1987, 155, 1349-1349.	4.0	11
97	A Critical Assessment of the Role of Second-Look Surgery in Ovarian Carcinoma. Cancer Investigation, 1987, 5, 479-485.	1.3	2
98	Catheter complications associated with intraperitoneal chemotherapy. Gynecologic Oncology, 1986, 24, 41-50.	1.4	42
99	The assessment of fetal pulmonary maturity by fluorescence polarization (FP-value) of pooled vaginal amniotic fluid associated with ruptured membranes. International Journal of Gynecology and Obstetrics, 1985, 23, 481-488.	2.3	3
100	Fluorescence polarization: Comments on urine contamination. American Journal of Obstetrics and Gynecology, 1981, 139, 613-614.	1.3	2